<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455141</url>
  </required_header>
  <id_info>
    <org_study_id>RJBC1501</org_study_id>
    <nct_id>NCT02455141</nct_id>
  </id_info>
  <brief_title>Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer</brief_title>
  <acronym>TCTN</acronym>
  <official_title>Epirubicin-Cyclophosphamide Followed by Taxanes or Taxanes Plus Carboplatin in Triple-Negative Breast Cancerï¼šA Prospective, Randomized, Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare disease-free survival (DFS) rate of adjuvant chemotherapy
      epirubicin-cyclophosphamide followed by weekly paclitaxel or docetaxel (EC-T), or weekly
      paclitaxel or docetaxel-carboplatin (EC-TCb) in triple-negative breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plans to enroll triple-negative breast cancer patients who have complete tumor
      removal. Patients are randomized to receive either EC-wP/T or EC-wP/TCb adjuvant
      chemotherapy. For triple-negative breast cancer, a subgroup of triple-negative breast cancer
      has DNA repairement deficiency and adding carboplatin to paclitaxel may improve DFS on the
      basis of weekly paclitaxel adjuvant chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>to compare the disease-free survival among two treatment arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>to compare the overall survival among two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutropenia fever</measure>
    <time_frame>up to 7 months</time_frame>
    <description>to compare the neutropenia fever among two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3-4 side effects</measure>
    <time_frame>up to 7 months</time_frame>
    <description>to compare the grade 3-4 side effects among two treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">970</enrollment>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>Taxanes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxanes plus carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel + Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin plus Cyclophosphamide</intervention_name>
    <description>Epirubicin 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4</description>
    <arm_group_label>Taxanes</arm_group_label>
    <arm_group_label>Taxanes plus carboplatin</arm_group_label>
    <other_name>EC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxanes</intervention_name>
    <description>Paclitaxel: 80mg/m2, d1, qw*12 or Docetaxel: 80-100mg/m2,d1,q3w*4</description>
    <arm_group_label>Taxanes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxanes plus Carboplatin</intervention_name>
    <description>Paclitaxel: 80mg/m2, d1,d8,d15, q4w*4 Carboplatin AUC=2, d1,d8,d15, q4w*4 or Docetaxel: 75mg/m2,d1,q3w*4 plus Carboplatin AUC=5-6, d1, q3w*4</description>
    <arm_group_label>Taxanes plus carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Histologically confirmed adenocarcinoma of the breast, completely tumor removal by
             either modified radical mastectomy or local excision plus axillary lymph node
             dissection (i.e., breast conservation therapy) or sentinel node biopsy. (Tumor-free
             margins at least 1 mm for both invasive and noninvasive carcinoma except for lobular
             carcinoma in situ (less than 1 mm allowed);

          -  Tumor specimens are available for estrogen receptor (ER), progesterone receptor (PgR)
             and Her2 (human epidermal-growth-factor receptor 2) detection, patients should be with
             triple negative breast cancer. Triple-negative disease is defined as ER &lt;1%
             positivity, PgR &lt;1% positivity, and negativity for Her2 (IHC (immunohistochemistry)
             0-1+ or FISH (fluorescence in situ hybridization) negative);

          -  Adequate bone marrow function

          -  Adequate liver and renal function

          -  Eastern Cooperative Oncology Group (ECOG) Performance Score 0-1;

          -  Women with potential child-bearing must have a negative pregnancy test (urine or
             serum) within 7 days of drug administration and agree to use an acceptable method of
             birth control to avoid pregnancy for the duration of the study;

          -  Written informed consent according to the local ethics committee requirements.

        Exclusion Criteria:

          -  Prior systemic of breast cancer, including chemotherapy;

          -  Metastatic breast cancer;

          -  With a history of malignant tumor except uterine cervix cancer in situ or skin basal
             cell carcinoma;

          -  Patients with medical conditions that indicate intolerant to adjuvant therapy and
             related treatment, including uncontrolled pulmonary disease, diabetes mellitus, severe
             infection, active peptic ulcer, coagulation disorder, connective tissue disease or
             myelo-suppressive disease;

          -  Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is
             known to be HIV positive;

          -  Contraindication for using dexamethasone;

          -  History of congestive heart failure, uncontrolled or symptomatic angina pectoris,
             arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP&gt;180
             mmHg or diastolic BP&gt;100 mmHg);

          -  Has peripheral neuropathy no less than grade 1;

          -  Patient is pregnant or breast feeding;

          -  Patients with psychiatric disorder or other diseases leading to incompliance to the
             therapy;

          -  Known severe hypersensitivity to any drugs in this study;

          -  Treatment with any investigational drugs within 30 days before the beginning of study
             treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunwei Shen, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Ruijin Hospital of Shanghai JiaoTong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaosong Chen, Dr.</last_name>
    <phone>+8621-64370045</phone>
    <phone_ext>602205</phone_ext>
    <email>chenxiaosong0156@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangjin Chen, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Maternal and Child Health Care Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anqin Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoqiang Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Jiangyin People's Hospital</name>
      <address>
        <city>Jiangyin</city>
        <state>Jiangsu</state>
        <zip>214400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Shao, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Wujiang District</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Wang, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Obstetrics &amp; Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kejin Wu, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai JiaoTong University School of Medicine, Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunwei Shen, professor</last_name>
      <phone>0086-021-64370045</phone>
      <phone_ext>602205</phone_ext>
      <email>kwshen@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Huangpu District, Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jialin Bao, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai International Peace Maternal and child health care hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>QI He, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ninth People's Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanyu Guo, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiaxin Maternal and Child Health Care Hospital</name>
      <address>
        <city>Jiaxin</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juanying Zhu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lishui People's Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Shi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Medical Treatment Center Lihuili Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weizhu Wu, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Women and Children's Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanwen Li, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rui'an People's Hospital</name>
      <address>
        <city>Rui'an</city>
        <state>Zhejiang</state>
        <zip>325200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou Central Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>318000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuechu Dai, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhoushan Hospital</name>
      <address>
        <city>Zhoushan</city>
        <state>Zhejiang</state>
        <zip>316000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xia Qiu, MD.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11;357(15):1496-506.</citation>
    <PMID>17928597</PMID>
  </reference>
  <reference>
    <citation>MartÃ­n M, RodrÃ­guez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Santaballa A, RodrÃ­guez CA, Crespo C, Abad M, DomÃ­nguez S, FloriÃ¡n J, Llorca C, MÃ©ndez M, Godes M, Cubedo R, Murias A, Batista N, GarcÃ­a MJ, Caballero R, de Alava E. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat. 2010 Aug;123(1):149-57. doi: 10.1007/s10549-009-0663-z.</citation>
    <PMID>20037779</PMID>
  </reference>
  <reference>
    <citation>Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4.</citation>
    <PMID>25092775</PMID>
  </reference>
  <reference>
    <citation>von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, KÃ¼mmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30.</citation>
    <PMID>24794243</PMID>
  </reference>
  <reference>
    <citation>Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O, Shen KW. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. PLoS One. 2014 Sep 23;9(9):e108405. doi: 10.1371/journal.pone.0108405. eCollection 2014.</citation>
    <PMID>25247558</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kunwei Shen</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>chemptherapy</keyword>
  <keyword>triple negative</keyword>
  <keyword>taxanes</keyword>
  <keyword>carboplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

